Centogene and Takeda Extend Partnership for Lysosomal Storage Disorder Testing
Centogene has extended its partnership with Takeda to diagnose patients with lysosomal storage disorders (LSDs).
Read MorePosted by Andy Lundin | Apr 11, 2023 | Company News |
Centogene has extended its partnership with Takeda to diagnose patients with lysosomal storage disorders (LSDs).
Read MorePosted by Andy Lundin | Apr 11, 2023 | Colorectal |
A new report shows Saudi Arabia has a high percentage of respondents who never took colon cancer tests, far higher than the global average.
Read MorePosted by Andy Lundin | Apr 5, 2023 | Lab Management |
TestDirectly, a direct-to-consumer (DTC) web portal, now supports provider insurance discovery and insurance eligibility checks.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Amplification Technologies, Prostate |
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Cardiovascular, Kidney Disease |
A new proteomic risk model for cardiovascular disease was found to be more accurate than current methods of measuring cardiac risk
Read More